New development in Valley fever vaccine for companion animalsOctober 15, 2018A novel Valley fever sub-unit vaccine for companion animals has been found by Mazen Animal Health to reduce the burden of coccidioides—the fungus that can cause Valley fever—in mice.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy treatment in 18 dogs. Those that received the vaccine lived more than twice as long as the historical, matched control group, with median survival times of 956 days compared to 423 days. The expanded clinical trial is designed to collect additional safety data for the vaccine in dogs that have undergone amputation of the affected limb and have already completed chemotherapy. If the treatment is found to be as safe and effective as it appeared in the initial clinical trial, Aratana will be given full licensure, allowing it to make the drug commercially available. Live Listeria Vector (AT-014) is created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells. It is designed to supplement standard osteosarcoma treatment of amputation …
Boehringer Ingelheim, Merial launch Recombitek Oral BordetellaFebruary 14, 2018Merial, now part of Boehringer Ingelheim, has launched Recombitek Oral Bordetella, an oral vaccine shown to be effective against canine infectious tracheobronchitis caused by Bordetella bronchiseptica, the company reported. Clinical studies suggest that as a mucosal vaccine, it offers dogs a robust immune response after a single dose, according to the manufacturer. B. bronchiseptica, one of the primary pathogens responsible for canine infectious respiratory disease complex, is unique in its ability to evade the immune system for weeks to months. During this time, a dog that appears clinically normal could be exposing other dogs. "For many dogs, oral delivery may mean a less stressful experience without the unpleasant sneeze backs of alternative vaccines delivered through the nose," said Zach Mills, DVM, executive director of Boehringer Ingelheim's U.S. Pet Vet Veterinary Professional Services. "The packaging's flip-top vial cap allows for easy opening by veterinary staff, and the safe, needle-free pipette simplifies the vaccination process while reducing risk of injury." Recombitek Oral Bordetella is administered into the dog's buccal cavity. Recombitek vaccines are backed by the Pet Vaccines Customer Satisfaction Guarantee. Visit boehringer-ingelheim.com for more information.
Strangles vaccine within reach for horsesFebruary 12, 2018Scientists from the Animal Health Trust (AHT), the Swedish University of Agricultural Sciences, the Karolinska Institute, and Intervacc AB, have developed a new protein-based vaccine to protect horses from strangles. Strangles, caused by Streptococcus equi bacteria, leads to large pus-filled abscesses in horses' throat and neck. The research was recently published in Vaccine. " … Our Strangvac vaccine protected over 80 percent of horses from this dreadful disease," said Jan-Ingmar Flock, Ph.D., CEO of Intervacc AB, the company that produced the vaccine. "Strangles is a scourge of the equine world and the development of Strangvac has the potential to prevent many thousands of horses from falling ill each year." "Strangvac is an extremely exciting vaccine," said Dr. Andrew Waller, head of bacteriology at AHT. "The vaccine was designed using information from sequencing the DNA of Streptococcus equi and highlights the potential that the genome-era heralds for improving the health of animals and people. Improving the health of horses is a core aim of the Animal Health Trust and we are proud to have helped make this vaccine a reality towards finally breaking the hold this disease currently has on our …
Aratana Therapeutics secures USDA conditional license for canine osteosarcoma vaccineJanuary 10, 2018Aratana Therapeutics announced that its canine osteosarcoma vaccine, Live Listeria Vector (AT-014), has been granted a conditional license by the USDA Center for Veterinary Biologics for the treatment of dogs diagnosed with osteosarcoma, 1 year of age or older. The vaccine is a novel immunotherapy developed by using a listeria-based antigen delivery system licensed from Advaxis Inc. "Osteosarcoma is the most common primary bone tumor in dogs and, since there haven't been advances to raise the standard of care in nearly 20 years, dogs often face a poor prognosis," said Ernst Heinen, DVM, Ph.D., chief development officer of Aratana Therapeutics. "We are hopeful that our canine osteosarcoma vaccine will be a new tool for veterinary oncologists to prolong survival in dogs with osteosarcoma." According to the company, the vaccine is a lyophilized formulation of a modified live, attenuated strain of listeria that activates cytotoxic T-cells. The therapeutic expresses a tumor-associated antigen that directs T-cells to fight cancer cells, even after the bacteria are cleared; the therapeutic capitalizes on the dog's immune system and its ability to attack bacterial infections, redirecting it to fight cancer cells, the company stated. Data from a clinical study …
UA researchers get $4.8 million to develop valley fever vaccineSeptember 6, 2017The University of Arizona's (UA) efforts to prevent valley fever in dogs received a boost in the way of a $4.8 million, four-year grant from the National Institutes of Health, providing the funding necessary to get the disease's delta-CPS1 vaccine to market, according to John Galgiani, MD, director of the UA Valley Fever Center for Excellence and principal investigator of the NIH grant. The vaccine, which could hit the market as soon as five years from now, will be developed for dogs first, but the end goal is to use it in humans, as well, according to Dr. Galgiani. There is currently no prevention or cure for valley fever, which is potentially deadly in both humans and dogs. Every year, an estimated 30,000 people and 60,000 dogs in Arizona get sick from valley fever, also known as coccidioidomycosis, according to UA. The cocci fungus that causes the disease is found mainly in dusty areas of Arizona and California, and it contributed to the deaths of 54 people in Arizona last year, state officials said. Treatment for valley fever is expensive: $4 to $6 per-day meds, blood tests, and additional …
Zoetis: Lepto vaccine may be used with all maresDecember 30, 2016The equine leptospirosis vaccine Lepto EQ Innovator is now approved for use in broodmares during the entire pregnancy, manufacturer Zoetis Inc. reported.
Boehringer to sell vaccine lines to ElancoOctober 5, 2016Elanco Animal Health plans to acquire more than 40 vaccines from Boehringer Ingelheim Vetmedica Inc. in a transaction valued at $885 million, the companies announced today.
